Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL2 interacting protein 3 pseudogene 9 (BNIP3P9) is annotated as a pseudogene, meaning it is a DNA sequence that closely resembles a known functional gene (in this case, BNIP3), but contains disabling mutations or lacks regulatory elements necessary for expression, so it does not encode a functional protein[1][5][11][14]. Pseudogenes like BNIP3P9 may be transcribed in some circumstances but typically do not exert biological effects at the protein level. They are not considered disease targets or functional molecules such as receptors, enzymes, or transporters. While the parental BNIP3 gene encodes a mitochondrial protein involved in apoptosis and autophagy, pseudogenes such as BNIP3P9 do not share these functions[3][4][7]. Some pseudogenes can have regulatory RNA-based roles (acting as microRNA sponges or antisense transcripts), but there is no evidence for BNIP3P9 having such activity[8][14]. In summary, BNIP3P9 is best described as a non-functional genomic element derived from BNIP3, with no established protein product or therapeutic role.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 9 (BNIP3P9).